Glioblastoma drug developer files for $75M IPO

The Israeli biotech Vascular Biogenics has filed plans to raise $75 million in an IPO on Nasdaq. According to its F-1, the biotech is engaged in R&D work on new drugs to fight cancer and immune-inflammatory conditions. Its lead drug, VB-111, gained fast track status at the FDA for glioblastoma and is slated to begin Phase III in Q1 2015. Another drug, VB-201, "is an oral small molecule we are currently evaluating in Phase II clinical trials for psoriasis and for ulcerative colitis." The company plans to trade under the symbol "VLBX." F-1

Suggested Articles

The VC shop raised the money across two funds that will deploy cash to help biotechs get started and grow into more established players.

Gilead Sciences' Kite Pharma enlisted Teneobio’s antibody technology in its work on new CAR-T therapies for patients with multiple myeloma.

Nearly two years after raising $75 million, iTeos Therapeutics is picking up $125 million to push its lead assets through phase 1/2 trials.